Related Experiment Videos
High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic
1Department of Medicine, Huddinge Hospital, Sweden.
Summary
This study shows that 2-chloro-2'-deoxyadenosine (CdA) effectively treats chronic lymphocytic leukemia (CLL), achieving high complete remission rates with manageable toxicity in previously treated patients.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy.
- Previously treated CLL patients often require alternative therapeutic strategies.
Purpose of the Study:
- To evaluate the efficacy of 2-chloro-2 extquotesingle-deoxyadenosine (CdA) in previously treated CLL patients.
- To identify predictors of response to CdA treatment.
Main Methods:
- Eighteen CLL patients received monthly courses of intravenous CdA (0.12 mg/kg/day for 5 days).
- Treatment response and toxicity were monitored.
Main Results:
- A 39% complete remission (CR) rate and a 67% overall response rate were observed.
- Thrombocytopenia was the primary dose-limiting toxicity.
- Rapid lymphocyte count reduction after the first course predicted response.
Conclusions:
- CdA demonstrates a high CR rate with acceptable toxicity in previously treated CLL.
- A treatment strategy for optimal response and toxicity management is proposed.